Trials / Completed
CompletedNCT00148369
A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 31 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 35 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate clinical and serologic outcomes after the discontinuation of liatermin therapy as assessed by development of new clinical conditions beyond those expected in patients with advancing Parkinson's disease. In addition, the development or resolution of anti-r-metHuGDNF binding and neutralizing antibodies will be monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Safety observation | Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug. |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-11-01
- Completion
- 2007-09-01
- First posted
- 2005-09-08
- Last updated
- 2010-02-19
Source: ClinicalTrials.gov record NCT00148369. Inclusion in this directory is not an endorsement.